EAM
REGN icon

Erste Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Erste Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.5M Sell
38,716
-18,493
-32% -$12.6M 0.19% 127
2026
Q1 		$42.9M Buy
57,209
+5,160
+10% +$3.95M 0.4% 65
2025
Q4 		$40.5M Buy
52,049
+3,313
+7% +$2.25M 0.34% 73
2025
Q3 		$27.3M Sell
48,736
-4,661
-9% -$2.64M 0.26% 100
2025
Q2 		$27.9M Buy
53,397
+16,364
+44% +$9.13M 0.23% 97
2025
Q1 		$23.6M Sell
37,033
-3,349
-8% -$2.3M 0.3% 83
2024
Q4 		$28.6M Sell
40,382
-257
-0.6% -$216K 0.35% 70
2024
Q3 		$42.5M Buy
40,639
+1,806
+5% +$2.01M 0.51% 52
2024
Q2 		$40.8M Sell
38,833
-3,115
-7% -$3.02M 0.54% 52
2024
Q1 		$40.5M Buy
41,948
+1,068
+3% +$1.02M 0.55% 54
2023
Q4 		$36M Buy
40,880
+2,410
+6% +$1.98M 0.53% 56
2023
Q3 		$32.1M Sell
38,470
-1,383
-3% -$1.09M 0.55% 60
2023
Q2 		$28.2M Buy
39,853
+413
+1% +$318K 0.5% 62
2023
Q1 		$32M Buy
39,440
+7,292
+23% +$5.5M 0.61% 51
2022
Q4 		$23.2M Sell
32,148
-1,987
-6% -$1.47M 0.49% 62
2022
Q3 		$23.6M Buy
34,135
+857
+3% +$539K 0.53% 57
2022
Q2 		$19.9M Buy
33,278
+1,077
+3% +$700K 0.44% 65
2022
Q1 		$22.3M Sell
32,201
-1,055
-3% -$667K 0.43% 65
2021
Q4 		$21.5M Sell
33,256
-1,714
-5% -$1.05M 0.39% 76
2021
Q3 		$21.2M Buy
34,970
+3,500
+11% +$2.17M 0.42% 76
2021
Q2 		$17.2M Sell
31,470
-1,650
-5% -$836K 0.34% 82
2021
Q1 		$15.6M Buy
33,120
+250
+0.8% +$122K 0.38% 76
2020
Q4 		$15.9M Sell
32,870
-2,800
-8% -$1.51M 0.44% 71
2020
Q3 		$20.5M Sell
35,670
-330
-0.9% -$200K 0.7% 41
2020
Q2 		$22M Buy
36,000
+26,500
+279% +$15M 0.88% 27
2020
Q1 		$4.49M Hold
9,500
– – 0.26% 111
2019
Q4 		$3.55M Hold
9,500
– – 0.16% 142
2019
Q3 		$2.6M Hold
9,500
– – 0.14% 156
2019
Q2 		$2.95M Sell
9,500
-7,850
-45% -$2.61M 0.16% 138
2019
Q1 		$7.02M Sell
17,350
-8,550
-33% -$3.52M 0.39% 59
2018
Q4 		$9.45M Buy
+25,900
New +$9.48M 0.63% 36

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MCI
McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Erste Asset Management's REGN Position: Q2 2026 in Review

Erste Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 32% in Q2 2026, selling an estimated $12.6M and leaving 38,716 shares worth $24.5M. The position accounts for 0.19% of the portfolio, ranked #127.

Erste Asset Management first reported a position in REGN in Q4 2018 and has held it in 31 quarters since. The position peaked at $42.9M in Q1 2026. 480 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Erste Asset Management held 38,716 shares of Regeneron Pharmaceuticals worth $24.5M as of Q2 2026.
  • Erste Asset Management sold 18,493 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $12.6M.
  • Regeneron Pharmaceuticals made up 0.19% of Erste Asset Management's portfolio in Q2 2026, its #127 holding.
  • Erste Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
  • Erste Asset Management's Regeneron Pharmaceuticals position peaked at $42.9M in Q1 2026.
  • 480 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.